MAIA Biotechnology

FDA clears U.S. trial of MAIA lung cancer drug for third-line patients

FDA · lung cancer · 6 min

The FDA has cleared MAIA Biotechnology to open U.S. enrollment in the expanded Phase 2 THIO-101 trial of ateganosine for third-line non-small cell lung cancer. This milestone, combined with Fast Track designation, positions MAIA for potential Accelerated Approval and shifts the competitive landscape in late-line NSCLC.